Aldeyra Therapeutics (ALDX) Operating Expenses (2013 - 2026)

Aldeyra Therapeutics' Operating Expenses history runs 14 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• Quarterly Operating Expenses fell 65.98% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.4 million (down 53.58% YoY) and the FY2025 annual result came in at $35.3 million, down 41.34% from the prior year.
• Operating Expenses was $3.5 million for Q1 2026 at Aldeyra Therapeutics, down from $6.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.0 million in Q2 2024 and bottomed at $3.5 million in Q1 2026.
• A 5-year average of $12.0 million and a median of $10.4 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 171.87% — and 2026, when it tumbled 65.98%.
• Aldeyra Therapeutics' Operating Expenses stood at $13.7 million in 2022, then slumped by 55.48% to $6.1 million in 2023, then surged by 171.87% to $16.6 million in 2024, then tumbled by 59.78% to $6.7 million in 2025, then plunged by 46.81% to $3.5 million in 2026.
• Business Quant data shows ALDX's Operating Expenses at $3.5 million in Q1 2026, $6.7 million in Q4 2025, and $8.0 million in Q3 2025.